Agenus Inc. (AGEN) Stock Price

AGENStock

$7.66+80.24%52W

Market Cap$344.77M

P/E2740.37x

PEG Ratio1.44

Div yield—

Beta1.39

AGEN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)125.96%

Price vs S&P 500 (4W)-3.59%

PEG Ratio1.44

VGM Score71.63

P/E Ratio (Annual)2740.37x

Book Value / Share (Quarterly)$0.24

P/TBV (Annual)31.87x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)5.22%

Cash Flow / Share (Quarterly)$-2.27

Price vs S&P 500 (YTD)131.13%

Gross Margin (TTM)99.29%

Net Profit Margin (TTM)52.16%

EPS (TTM)$1.67

10-Day Avg Trading Volume1.14M

EPS Excl Extra (TTM)$1.67

Revenue Growth (5Y)5.31%

EPS (Annual)$0.00

ROI (Annual)-49.19%

Gross Margin (Annual)99.11%

Net Profit Margin (5Y Avg)-121.87%

Cash / Share (Quarterly)$0.91

P/E Basic Excl Extra (TTM)4.88x

Revenue Growth QoQ (YoY)40.18%

P/E Normalized (Annual)2740.37x

ROA (Last FY)0.05%

Revenue Growth TTM (YoY)24.46%

EBITD / Share (TTM)$3.48

ROE (5Y Avg)-132.67%

Operating Margin (TTM)87.93%

Cash Flow / Share (Annual)$-2.19

P/B Ratio92.25x

P/B Ratio (Quarterly)153.49x

Net Income / Employee (Annual)$1,400

EV / Revenue (TTM)4.63x

Net Interest Coverage (TTM)0.96x

ROA (TTM)31.05%

EV / EBITDA (TTM)4.93x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)0.41x

Quick Ratio (Quarterly)0.37x

3-Month Avg Trading Volume3.18M

52-Week Price Return80.24%

P/E Incl Extra (TTM)4.88x

Revenue / Employee (TTM)$1,529,200

Tangible BV / Share (Quarterly)$0.60

P/S Ratio (Annual)2.76x

Asset Turnover (Annual)0.50x

52-Week High$8.85

Operating Margin (5Y Avg)-64.44%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-71.97%

Tangible BV CAGR (5Y)-23.22%

26-Week Price Return137.89%

Quick Ratio (Annual)0.41x

13-Week Price Return125.29%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)0.38x

Enterprise Value$573.73M

Revenue / Share Growth (5Y)-17.78%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)-61.57%

Revenue / Employee (Annual)$1,409,800

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)-2.70%

Cash / Share (Annual)$0.08

3-Month Return Std Dev187.10%

Gross Margin (5Y Avg)96.94%

Net Income / Employee (TTM)$797,600

ROE (Last FY)-69.47%

Net Interest Coverage (Annual)1.74x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)2.89x

Receivables Turnover (TTM)35.82x

Total Debt / Equity (Quarterly)4.01x

EPS Incl Extra (TTM)$1.67

Receivables Turnover (Annual)102.05x

ROI (TTM)48.69%

P/S Ratio (TTM)2.54x

Pretax Margin (5Y Avg)-127.38%

Revenue / Share (Annual)$3.84

Tangible BV / Share (Annual)$2.02

Forward P/E37.54x

Price vs S&P 500 (52W)61.68%

P/E Ratio (TTM)4.88x

Year-to-Date Return143.95%

5-Day Price Return-0.13%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-47.40%

Net Profit Margin (Annual)0.10%

Month-to-Date Return2.13%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$3.05

Operating Margin (Annual)70.54%

LT Debt / Equity (Annual)0.37x

ROI (5Y Avg)-75.46%

P/E Excl Extra (TTM)4.88x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$1.67

P/TBV (Quarterly)79.78x

P/B Ratio (Annual)24.02x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)50.45%

Book Value / Share (Annual)$2.68

Price vs S&P 500 (13W)123.34%

Beta1.39x

P/FCF (Annual)346.31x

Revenue / Share (TTM)$3.24

ROE (TTM)76.63%

52-Week Low$2.71

vGradeB

gGradeB

mGradeA

vgmGradeB

AGEN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 7, 2026	$0.04	-$0.01	-125.00%(-$0.05)
Q1 2026	May 11, 2026	$1.80	-$0.03	-101.77%(-$1.83)
Q4 2025	Mar 16, 2026	-$1.30	$0.68	+152.37%(+$1.98)
Q3 2025	Nov 10, 2025	$2.20	-$1.16	-152.92%(-$3.36)
Q2 2025	Aug 11, 2025	$1.35	-$1.00	-173.89%(-$2.35)

AGEN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
AGENAgenus Inc.	B	B	A	$7.66
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Agenus Inc.

Agenus is a clinical-stage immunotherapy company developing therapies to activate the immune system against cancer and infectious disease. Its pipeline includes immune-modulatory antibodies (botensilimab, a CTLA-4 inhibitor; balstilimab, a PD-1 inhibitor), adoptive cell therapies through subsidiary MiNK Therapeutics, and vaccine adjuvants via subsidiary SaponiQx. The company operates in-house cGMP manufacturing and clinical operations capabilities to support product development.